Substance Withdrawal Syndrome: Clinical Trials

86 trials for Substance Withdrawal Syndrome, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

60 completed, 10 unknown, 5 recruiting, 4 terminated. 26 Not applicable, 17 Phase 2, 12 Phase 4, 11 Phase 3, 6 Phase 1.

By phase and status

PhaseTrialsStatus
Not applicable26Completed 19, Unknown 3, Active not recruiting 1, Not yet recruiting 1, Terminated 1, Withdrawn 1
Phase 217Completed 10, Unknown 2, Active not recruiting 1, Not yet recruiting 1, Recruiting 1, Terminated 1, Withdrawn 1
Phase 412Completed 8, Terminated 2, Recruiting 1, Unknown 1
Phase 311Completed 7, Unknown 2, Not yet recruiting 1, Recruiting 1
Phase 16Completed 5, Unknown 1

Follow Substance Withdrawal Syndrome: new trials by email Literature Review of Substance Withdrawal Syndrome trials Research Report on Substance Withdrawal Syndrome

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Dexmedetomidine for Invasive Ventilation In the NEOnate
Dexmedetomidine Injectable Solution, Glucose 5% Injectable Solution - Invasive Ventilation, Infant Pain
Phase 2 / Phase 3Not yet recruitingCentre Hospitalier Intercommunal Creteil2462027-01-012026-08-26
Preventox - a Digital Intervention for Patients With Intoxications in Intensive Care
Preventox, a digital self-help tool for patients with intoxications in intensive care., Preventox control group - Intoxication, Delirium Tremens (DTs)
Not applicableNot yet recruitingKarolinska Institutet502026-09-302026-09-23
Validation of the French Version of the Prediction of the Alcohol Withdrawal Severity Scale (PAWSS)
French version PAWSS - Addiction, Substance, Alcohol Use Disorder
RecruitingEtablissement Public de Santé Barthélemy Durand5452024-11-112025-02-25
Efficacy of XYZ for Withdrawal Syndrome
Tiaozhong-Yiqi Decoction, routine care - Substance Withdrawal Syndrome
Not applicableCompletedChongqing Jiangbei Hospital of Traditional Chinese Medicine802024-05-012026-04-27
Non-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3
Transcutaneous Cervical Vagal Nerve Stimulation, Sham Stimulation, [F-18]Fallypride - Withdrawal Symptoms, Opioid Use Disorder
Phase 3RecruitingEmory University1032024-02-202026-03-27
Novel Use of Probenecid to Alleviate Symptoms of Opioid Withdrawal
Probenecid - Chronic Pain, Drug Dependence of Morphine Type
Phase 2RecruitingUniversity of Calgary402023-10-312026-05-01
Characterization of the Pattern of Consumption and Withdrawal Syndrome From Dual Cannabis and Tobacco Use
Cannabis Dependence, Tobacco Use
UnknownCristina Martínez Martínez2822023-07-012023-07-03
Neurostimulation to Improve NOWS Outcomes
Sparrow Fledging Therapy System, Sham Sparrow Fledging Therapy System - Neonatal Opioid Withdrawal Syndrome, Neonatal Abstinence Syndrome
Not applicableActive not recruitingSpark Biomedical, Inc.522022-07-272026-06-02
Delivering Transcutaneous Auricular Neurostimulation to Improve Relapse Prevention in Opioid Use Disorder
Sparrow Ascent Therapy System, Lofexidine, Extended-release injectable naltrexone - Opioid-use Disorder, Opioid Withdrawal
Not applicableCompletedSpark Biomedical, Inc.1082022-05-272025-07-04
Prospective, Randomized, Open Label Controlled Trial To Evaluate The Safety And Efficacy Of Dexmedetomidine Use Beyond 24 Hours Compared With Midazolam In Children Admitted To Pediatric Intensive Care Unit at King Abdullah Specialist Children Hospital- Ministry of National Guard Health Affairs.
Dexmedetomidine, Midazolam - Dexmedetomidine, Midazolam
Phase 3UnknownKing Abdullah International Medical Research Center4302022-04-212023-04-27
Assessment of Analgesics and Sedatives in Mechanically Ventilated Patients With COVID-19
COVID-19, ARDS
CompletedWilkes University3532022-01-012023-04-26
The Effect of Honey on Lessening the Withdrawal Symptoms
Honey, Water - Smoking Cessation, Withdrawal Symptoms
Not applicableUnknownBuddhist Tzu Chi General Hospital1002021-09-032022-03-03
Phenobarbital for Severe Acute Alcohol Withdrawal Syndrome
Phenobarbital Sodium, Inactive placebo - Alcohol Withdrawal Delirium, Alcohol Withdrawal
Not applicableTerminatedUnity Health Toronto82021-06-112023-11-02
EA for PAAS: A pRCT
Electro-Acupuncture - Substance Withdrawal Syndrome
Not applicableUnknownChengdu University of Traditional Chinese Medicine10002021-06-012021-06-08
AduLt iatrogEnic withdRawal sTudy in the ICU (ALERT-ICU)
Withdrawal Syndrome, Iatrogenic Disease
CompletedWilkes University24372021-06-012022-07-29
Computerized Chemosensory-Based Orbitofrontal Cortex (CBOT) for Opioid Use Disorder
CBOT + TAU, Sham + TAU - Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe
Phase 2UnknownEvon Medics LLC1902021-03-262021-08-06
Novel Earpiece for Transcutaneous Auricular Neurostimulation (tAN) for Symptoms of Opioid Withdrawal
Sparrow Therapy System - Opioid-use Disorder, Opioid Withdrawal
Not applicableCompletedSpark Biomedical, Inc.62021-03-182021-08-19
Qualitative Understanding of Experiences With the SIMPLIFY Trial
Qualitative Interview - Cystic Fibrosis, Drug Withdrawal
CompletedBoston Children's Hospital1152020-12-232023-08-25
Phenobarbital vs Ativan for Alcohol Withdrawal in the Intensive Care Unit
Phenobarbital, Lorazepam - Alcohol Withdrawal, Alcohol Withdrawal Delirium
Phase 4UnknownOSF Healthcare System1422020-07-062020-10-08
Effects of T-bet B Cells in Persistent Virus Control After Discontinuance of NAs in CHB Patients
T-bet B cell - Chronic HBV Infection, Drug Withdrawal
CompletedChanghai Hospital452020-07-012023-09-08

Showing 20 of 86. Sign in to see all of them.

Narrower conditions

Opioid-Related Disorders (15)  ·  Alcohol Withdrawal Delirium (11)  ·  Substance-Related Disorders (10)  ·  Alcoholism (5)  ·  Behavior, Addictive (5)  ·  Marijuana Abuse (5)  ·  Tobacco Use Disorder (5)  ·  Alcohol Withdrawal Seizures (4)  ·  Critical Illness (4)  ·  Smoking Cessation (4)  ·  Agnosia (3)  ·  Chronic Pain (3)  ·  Delirium (3)  ·  Iatrogenic Disease (3)

Broader conditions

Chemically-Induced Disorders (86)  ·  Mental Disorders (84)  ·  Substance-Related Disorders (76)  ·  Pathological Conditions, Signs and Symptoms (26)  ·  Nervous System Diseases (19)  ·  Behavior (16)  ·  Signs and Symptoms (16)  ·  Narcotic-Related Disorders (15)  ·  Neurologic Manifestations (15)  ·  Alcohol-Induced Disorders (12)  ·  Alcohol-Induced Disorders, Nervous System (12)  ·  Alcohol-Related Disorders (12)  ·  Neurotoxicity Syndromes (12)  ·  Poisoning (12)

Interventions

Buprenorphine (4)  ·  Dexmedetomidine (4)  ·  Buprenorphine, Naloxone Drug Combination (3)  ·  Methadone (3)  ·  Tobacco Use Cessation Devices (3)  ·  Analgesics (2)  ·  Analgesics, Opioid (2)  ·  Baclofen (2)  ·  Clonidine (2)  ·  Levetiracetam (2)  ·  Lorazepam (2)  ·  Naltrexone (2)  ·  Narcotics (2)  ·  Nicotine (2)  ·  Phenobarbital (2)

Sponsors

Spark Biomedical, Inc. (4)  ·  Stanford University (3)  ·  Changhai Hospital (2)  ·  Southern Illinois University Carbondale (2)  ·  University of California, Los Angeles (2)  ·  Wilkes University (2)  ·  Aarhus University Hospital (1)  ·  Arizona State University (1)  ·  Assistance Publique - Hôpitaux de Paris (1)  ·  Banner Health (1)  ·  Boston Children's Hospital (1)  ·  Buddhist Tzu Chi General Hospital (1)  ·  Centre Hospitalier Intercommunal Creteil (1)  ·  Centre Hospitalier Universitaire, Amiens (1)  ·  Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal (1)

Countries

United States (42)  ·  Canada (8)  ·  France (6)  ·  China (5)  ·  Finland (2)  ·  Mexico (2)  ·  Norway (2)  ·  Thailand (2)  ·  Australia (1)  ·  Czechia (1)  ·  Denmark (1)  ·  Germany (1)  ·  Italy (1)  ·  Netherlands (1)  ·  Saudi Arabia (1)

Top investigators

David G Gilbert, PhD (2)  ·  Elisabeth B Salisbury, Ph.D. (2)  ·  Kathryn E Smith, PharmD, BCPS, BCCCP (2)  ·  Navid Khodaparast, PhD (2)  ·  Walter Ling, M.D. (2)  ·  Adam R Winstock, MBBS BSc MSc MRCP(UK) MRCP (1)  ·  Alain Dervaux (1)  ·  Anne Julie Frenette, M.Sc. (1)  ·  Ben Jong,de, MD (1)  ·  Bhagat Aulakh, MD (1)  ·  Brian L Erstad, PharmD, MCCM (1)  ·  Charles O'Brien, M.D./Ph.D. (1)  ·  Charles W. Gorodetzky (1)  ·  Christine Marx, M.D. (1)

Results publications

PMID 10776874, PMID 28866754, PMID 33348423, PMID 9559604, PMID 12751978, PMID 14574086, PMID 15714323, PMID 15818103, PMID 17107609, PMID 17205003, PMID 18621934, PMID 19244173, PMID 20944765, PMID 20951277, PMID 21105289, PMID 22325962, PMID 22566069, PMID 22882805, PMID 22898443, PMID 23184039, PMID 23188041, PMID 23709323, PMID 23755929, PMID 24657098, PMID 24821356, PMID 25602358, PMID 27542731, PMID 28157809, PMID 28793780, PMID 29292273, PMID 29881956, PMID 30113379, PMID 30569508, PMID 30920255, PMID 31352486, PMID 31504882, PMID 31829274, PMID 32002194, PMID 32034447, PMID 32157678, PMID 32222812, PMID 32329799, PMID 32392023, PMID 32863639, PMID 33423824, PMID 33515267, PMID 33620407, PMID 33735508, PMID 33966568, PMID 33985368

NIH funding

2015 (1), 2025 (1), 4UH3DA048502 (1), P60DA005186 (1), R01CA192940 (1), R01DA008067 (1), R01DA012289 (1), R01DA027068 (1), R01DA027131 (1), R01DA031006 (1), R01DA042074 (1), R01DA044125 (1), R44DA049616 (1), R44DA050360 (1)